- Conditions
- HCC
- Interventions
- GNOS-PV02, INO-9012, Pembrolizumab, CELLECTRA®2000 EP Device
- Biological · Drug · Device
- Lead sponsor
- Geneos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 115
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive, Metastatic Malignant Neoplasm, Recurrent Anal Canal Carcinoma, Recurrent Cervical Carcinoma, Recurrent Malignant Neoplasm, Recurrent Penile Carcinoma, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Refractory Malignant Neoplasm, Stage IV Anal Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8
- Interventions
- DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, Durvalumab
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- HIV-1-infection
- Interventions
- PENNVAX-GP, INO-6145, INO-9012, CELLECTRA® 2000
- Biological · Device
- Lead sponsor
- Steven Deeks
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- Los Angeles, California • San Francisco, California
- Conditions
- BRCA1/2 Mutation
- Interventions
- INO-5401, INO-9012, Cellectra 2000
- Drug · Device
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Respiratory Papillomatosis
- Interventions
- INO-3107, CELLECTRA® 2000
- Drug · Device
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Sacramento, California • Atlanta, Georgia + 7 more
- Conditions
- Multiple Myeloma
- Interventions
- CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs), Standard of care
- Biological · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- ER-Negative PR-Negative HER2-Negative Breast Cancer
- Interventions
- IT-pIL12-EP
- Biological
- Lead sponsor
- OncoSec Medical Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- HCC
- Interventions
- GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporation, Electroporation Device, INO-9012
- Biological · Device
- Lead sponsor
- Geneos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • New Orleans, Louisiana • Baltimore, Maryland + 4 more
- Conditions
- Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Long-standing Persistent Atrial Fibrillation
- Interventions
- Farapulse Catheter System, Low-dose Colchicine
- Device · Drug
- Lead sponsor
- Vivek Reddy
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 9
- States / cities
- Jonesboro, Arkansas • Ventura, California • Naples, Florida + 5 more
- Conditions
- Healthy Volunteers
- Interventions
- INO-A002, CELLECTRA® 2000, Dengue Fever Antibodies (IgG)
- Biological · Device
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Nivolumab, Irreversible Electroporation
- Drug · Procedure
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Extensive-stage Small Cell Lung Cancer
- Interventions
- Neoantigen DNA vaccine, Durvalumab, TDS-IM v2.0 Device, Peripheral blood draws
- Biological · Drug · Device + 1 more
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- HIV Infections
- Interventions
- PENNVAX-B, IL-12 DNA plasmids
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 3
- States / cities
- Rochester, New York • Philadelphia, Pennsylvania • Nashville, Tennessee
- Conditions
- Pancreatic Cancer
- Interventions
- IRE + intratumoral mitazalimab (CD40 antibody) injection, NanoKnife
- Drug · Device
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Metastatic Melanoma
- Interventions
- VCL-IM01 (encoding IL-2) with Electroporation
- Genetic
- Lead sponsor
- Vical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 4
- States / cities
- Mobile, Alabama • Denver, Colorado • Chicago, Illinois + 1 more
- Conditions
- Melanoma
- Interventions
- Tavokinogene Telseplasmid (tavo), OncoSec Medical System (OMS)
- Biological · Device
- Lead sponsor
- OncoSec Medical Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 6
- States / cities
- San Francisco, California • Santa Monica, California • Denver, Colorado + 3 more
- Conditions
- Prostate Cancer
- Interventions
- NanoKnife System, Stereotactic Body Radiation Therapy
- Device · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 8
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Hepatitis B
- Interventions
- INO-1800, INO-9112, Nucleos(t)ide Analogue Treatment
- Biological · Drug
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 7
- States / cities
- San Diego, California • Miami, Florida • Manhasset, New York + 4 more
- Conditions
- HIV-1 Infection, HIV Infections
- Interventions
- PENNVAX-B
- Biological
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cervical Cancer
- Interventions
- INO-3112, CELLECTRA™-5P
- Biological · Device
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Ann Arbor, Michigan • New York, New York
- Conditions
- Breast Cancer, Breast Carcinoma, Malignant Neoplasm of Breast
- Interventions
- Mammaglobin-A DNA Vaccine, Optional biopsy
- Biological · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Melanoma
- Interventions
- Tavo, Nivolumab, OncoSec Medical Electroporation Therapy System
- Drug · Device
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Healthy
- Interventions
- GLS-5300
- Biological
- Lead sponsor
- GeneOne Life Science, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- Papillomavirus Infections
- Interventions
- VGX-3100
- Biological
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 3
- States / cities
- Winston-Salem, North Carolina • Hopwood, Pennsylvania • Philadelphia, Pennsylvania